Liyang Shi Selected Research

compound 30

1/2022

Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liyang Shi Research Topics

Disease

7	Neoplasms (Cancer) 03/2022 - 11/2015
1	Melanoma (Melanoma, Malignant) 03/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Wounds and Injuries (Trauma) 01/2018
1	Inflammation (Inflammations) 01/2018
1	Infections 01/2018
1	Hyperthermia 11/2015

Drug/Important Bio-Agent (IBA)

5	HydrogelsIBA 03/2022 - 11/2015
3	Biocompatible Materials (Biomaterials)IBA 12/2019 - 09/2016
2	Pharmaceutical PreparationsIBA 01/2022 - 09/2016
2	Hyaluronic Acid (Hyaluronan)IBA 01/2018 - 12/2016
1	CytokinesIBA 03/2022
1	InterferonsIBA 03/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2022
1	Imiquimod (Aldara)FDA LinkGeneric 03/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2022
1	compound 30IBA 01/2022
1	7-azaindole dimerIBA 01/2022
1	Metal-Organic FrameworksIBA 01/2022
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	Type 4 Fibroblast Growth Factor ReceptorIBA 01/2022
1	SolutionsIBA 01/2018
1	Liposomes (Liposome)IBA 12/2016
1	PolymersIBA 12/2016

Therapy/Procedure

4	Injections 03/2022 - 11/2015
3	Therapeutics 03/2022 - 11/2015